MedTrace Logo

Omega 3 for Treatment of Depression in Patients With Heart Failure

NCT02057406 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2018-05-14

Study results available
· View outcomes & findings →

Summary

Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in heart failure patients with moderate to severe major depressive disorder.

Conditions

Interventions

DRUG

2:1 EPA/DHA

400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams

DRUG

High EPA

OTHER

Placebo

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Wei Jiang

    lead OTHER

Principal Investigators

  • Wei Jiang, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-05-19
Completion
2016-12-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057406 on ClinicalTrials.gov